Diatos

company

About

Diatos is a biopharmaceutical company developing innovative therapies for unmet medical needs in cancer.

  • 11 - 50

Details

Last Funding Type
Series D
Last Funding Money Raised
$12.80M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 1999
Number Of Employee
11 - 50
Operating Status
Active

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA.

Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$12.80M
Diatos has raised a total of $12.80M in funding over 2 rounds. Their latest funding was raised on Jul 3, 2007 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 3, 2007 Series D $12.80M 4 Detail

Investors

Number of Lead Investors
Number of Investors
4
Diatos is funded by 4 investors. Biotech Fund Flanders and NIF SMBC Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Biotech Fund Flanders Series D
NIF SMBC Ventures Series D
Sopartec Series D
Credit Agricole Entreprises Series D